🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Westmead
Clinical trial register · Australia

Clinical Trials in Westmead, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3335 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
3335
Studies in scope
all four open statuses
1809
Recruiting now
open to new participants
761
Lead sponsors
across recruiting studies
Top sites
Melbourne 32 Westmead 30 Brisbane 28 Clayton 22 Frankston 21
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC30 Children's Oncology Group20 Bristol-Myers Squibb17 AstraZeneca14 Western Sydney Local Health District12 Clear sponsor filter
Site location
Melbourne32 Westmead30 Brisbane28 Clayton22 Frankston21
All 78 locations
Target enrolment
to

Trials with a site in Westmead

30 of 3335 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558Ovarian Neoplasms, Ovarian Cancer
DrugsMvasi·Avastin·Sacituzumab tirumotecan·Bevacizumab
Merck Sharp & Dohme LLC
Phase 3
900
Westmead, Brisbane, East Melbourne
2026-02-16
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474Squamous Non-small Cell Lung Cancer
DrugsIntismeran autogene·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
180
Westmead, Woolloongabba, Nedlands
2025-12-12
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
DrugsCalderasib·Cetuximab
Merck Sharp & Dohme LLC
Phase 2
150
Randwick, Westmead, Melbourne
2025-12-04
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Xeloda·Adriamycin·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Camperdown, North Ryde, Westmead, Clayton
2025-06-30
Active, closed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
NCT06925750Pulmonary Arterial Hypertension
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
130
Camperdown, Westmead, Auchenflower, Melbourne
2025-05-12
Active, closed
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
NCT06504394Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
Drugs) Berahyaluronidase alfa·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
66
Westmead
2024-10-14
Active, closed
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346Essential Thrombocythemia
DrugsBomedemstat·Hydroxyurea
Merck Sharp & Dohme LLC
Phase 3
300
Westmead, Adelaide, Clayton, Heidelberg, Perth
2024-07-16
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,530
Macquarie University, Westmead, Brisbane, Frankston
2024-06-24
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
DrugsSacituzumab tirumotecan·Leucovorin·Fluorouracil·Adrucil
Merck Sharp & Dohme LLC
Phase 1/2
220
Westmead, Brisbane, East Melbourne, Frankston, Nedlands
2024-06-20
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
DrugsLiposomal doxorubicin·Xeloda·Abraxane·Taxol
Merck Sharp & Dohme LLC
Phase 3
1,200
Macquarie University, Westmead, Frankston, Murdoch
2024-04-14
Active, closed
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
NCT06307431Renal Cell Carcinoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
272
Macquarie University, Westmead, Brisbane, Murdoch
2024-04-10
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
780
Westmead, Brisbane, Murdoch
2024-04-03
Active, closed
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767Bladder Cancer
DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
230
Macquarie University, Westmead, South Brisbane, Nedlands
2024-03-28
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,310
Dubbo, Macquarie University, Westmead, Brisbane, Melbourne
2023-12-31
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,314
Macquarie University, Westmead, Brisbane, Clayton, Melbourne
2023-12-18
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Port Macquarie, Westmead, Ballarat Central, Epping, Frankston
2023-12-15
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
556
Kogarah, Westmead, Clayton, Melbourne
2023-11-12
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,089
Westmead, Wollstonecraft, Brisbane, Melbourne, Nedlands
2023-07-19
Active, closed
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC
Phase 2
129
Camperdown, Westmead, Auchenflower, Brisbane, South Brisbane
2023-03-16
Recruiting
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712Pulmonary Arterial Hypertension
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
42
Westmead
2023-01-19
Active, closed
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
NCT05468697Renal Cell Carcinoma
DrugsBelzutifan·Palbociclib
Merck Sharp & Dohme LLC
Phase 1/2
60
Macquarie University, Westmead, Frankston, Nedlands
2022-08-10
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
DrugsTaxotere·Paraplatin·Taxol·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
280
St Leonards, Westmead, Brisbane, Clayton, Melbourne, Subiaco
2022-02-03
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
DrugsCalderasib·Leucovorin·Adrucil·Cetuximab
Merck Sharp & Dohme LLC
Phase 1
830
Camperdown, Liverpool, Westmead, Clayton
2021-12-17
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
DrugsDocetaxel·Paclitaxel·Bevacizumab·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
643
Westmead, Brisbane, Melbourne, Subiaco
2021-12-13
Active, closed
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
NCT04938817Small Cell Lung Carcinoma
DrugsMK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab·R-DXd
Merck Sharp & Dohme LLC
Phase 1/2
110
Westmead, Brisbane, Clayton, Perth
2021-08-19
Active, closed
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
NCT04976634Neoplasm Malignant
DrugsBelzutifan·Lenvatinib·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
730
Gosford, Westmead, Epping, Malvern
2021-08-18
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
DrugsLiposomal doxorubicin·Xeloda·Abraxane·Taxol
Merck Sharp & Dohme LLC
Phase 3
342
Macquarie Park, Westmead, Frankston, Nedlands
2021-06-18
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
DrugsKeytruda·Cisplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
714
Westmead, Herston
2018-12-17
Active, closed
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03553836Melanoma
DrugsKeytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
976
North Sydney, Westmead, Cairns, Southport, Woolloongabba, Adelaide, Kurralta Park, Melbourne
2018-09-12
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
DrugsPemetrexed·Keytruda·Gemcitabine·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
797
Orange, Westmead
2018-04-24
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-australia/city/westmead

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,335 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Westmead that also match the filters currently applied.

How many clinical trials are recruiting in Westmead?

13 of the 30 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Westmead), 30 studies
PhaseStudiesRecruitingShare
Phase 317856.7%
Phase 28326.7%
Phase 1/24113.3%
Phase 1113.3%

Most active sponsors

Lead sponsors with the most studies (Westmead)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC3013
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.